Hematocrit changes over time by treatment group and sex. Hematocrit changes over time according to baseline hematocrit categories in males (A) and females (B). Compared with placebo, canagliflozin increased hematocrit levels irrespective of baseline hematocrit status in both sexes. The mean hematocrit values and 95% CIs were calculated using a mixed-effects model for repeated measures. This model incorporated the fixed effects of the treatment arm, trial, trial visit, and treatment-by-visit interaction. The I bars indicate 95% CIs. Anemia was defined as a hematocrit level of <39% in males or <36% in females. Erythrocytosis was defined as a hematocrit level of >49% in males or >48% in females.